Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANRO Stock Forecast 2025-2026
$2.93
Current Price
$77.16M
Market Cap
Buy 7
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ANRO Price Targets
+514.3%
To High Target of $18.00
+241.3%
To Median Target of $10.00
+36.5%
To Low Target of $4.00
ANRO Price Momentum
+15.8%
1 Week Change
+29.1%
1 Month Change
-75.1%
1 Year Change
-30.7%
Year-to-Date Change
-83.3%
From 52W High of $17.55
+83.1%
From 52W Low of $1.60
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Alto Neuroscience (ANRO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ANRO and similar high-potential opportunities.
Latest ANRO Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, ANRO has a bullish consensus with a median price target of $10.00 (ranging from $4.00 to $18.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $2.93, the median forecast implies a 241.3% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Justin Walsh at Jones Trading, projecting a 514.3% upside. Conversely, the most conservative target is provided by Laura Chico at Wedbush, suggesting a 36.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANRO Analyst Ratings
7
Buy
1
Hold
0
Sell
ANRO Price Target Range
Low
$4.00
Average
$10.00
High
$18.00
Current: $2.93
Latest ANRO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANRO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2025 | Wedbush | Laura Chico | Neutral | Reiterates | $4.00 |
| Apr 7, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Initiates | $10.00 |
| Dec 16, 2024 | Jones Trading | Justin Walsh | Buy | Initiates | $18.00 |
| Nov 13, 2024 | Stifel | Paul Matteis | Buy | Maintains | $10.00 |
| Oct 23, 2024 | Baird | Brian Skorney | Outperform | Maintains | $10.00 |
| Oct 23, 2024 | Wedbush | Laura Chico | Neutral | Downgrade | $4.00 |
| Sep 10, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $29.00 |
| Sep 3, 2024 | Wedbush | Laura Chico | Outperform | Initiates | $29.00 |
| Jun 21, 2024 | Rodman & Renshaw | Elemer Piros | Buy | Initiates | $43.00 |
| Mar 25, 2024 | Stifel | Paul Matteis | Buy | Reiterates | $32.00 |
| Feb 27, 2024 | Stifel | Paul Matteis | Buy | Initiates | $32.00 |
| Feb 27, 2024 | Jefferies | Andrew Tsai | Buy | Initiates | $33.00 |
| Feb 27, 2024 | Baird | Brian Skorney | Outperform | Initiates | $32.00 |
Alto Neuroscience Inc. (ANRO) Competitors
The following stocks are similar to Alto Neuroscience based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alto Neuroscience Inc. (ANRO) Financial Data
Alto Neuroscience Inc. has a market capitalization of $77.16M with a P/E ratio of -1.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -38.0%.
Valuation Metrics
Market Cap
$77.16M
Enterprise Value
$-55,536,104
P/E Ratio
-1.2x
PEG Ratio
-1.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+202.7%
Current Ratio
22.5x
Debt/Equity
19.0x
ROE
-38.0%
ROA
-22.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Alto Neuroscience Inc. (ANRO) Business Model
About Alto Neuroscience Inc.
What They Do
Develops precision therapeutics for psychiatric disorders.
Business Model
The company utilizes advanced neurobiological insights and digital tools to create tailored treatments for mental health conditions such as depression and anxiety. By employing AI-driven patient profiling and biomarker-based approaches, Alto Neuroscience generates revenue through the development and commercialization of personalized therapeutic solutions, improving treatment efficacy and patient outcomes.
Additional Information
Alto Neuroscience is positioned at the intersection of biotechnology and digital health, offering innovative solutions that may transform psychiatric treatment paradigms. Their focus on personalized medicine aims to enhance patient experiences and reduce the trial-and-error approach commonly associated with mental health medications.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
76
CEO
Dr. Amit Etkin M.D., Ph.D.
Country
United States
IPO Year
N/A
Website
www.altoneuroscience.comAlto Neuroscience Inc. (ANRO) Latest News & Analysis
Latest News
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights
8 days ago
Quick Summary
Alto Neuroscience (NYSE: ANRO) reported Q1 2025 financial results, emphasizing advancements in its pipeline for neuropsychiatric treatments.
Why It Matters
Alto Neuroscience's financial results and pipeline progress signal advancements in neuropsychiatric treatments, potentially impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Alto Neuroscience (NYSE: ANRO) announced multiple presentations at the SOBP Annual Meeting in April 2025, highlighting advancements in its precision psychiatry pipeline for neuropsychiatric disorders.
Why It Matters
Alto Neuroscience's presentations at a major psychiatry conference highlight advancements in their drug pipeline, potentially boosting investor confidence in future growth and market position.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Alto Neuroscience (NYSE: ANRO) will present at the JonesResearch Virtual CNS Day on April 29, 2025, at 12:30 pm ET, and will also hold one-on-one investor meetings.
Why It Matters
Alto Neuroscience's presentation and investor meetings may signal upcoming developments in their drug pipeline, influencing market sentiment and stock performance for $ANRO.
Source: Business Wire
Market Sentiment:
Neutral
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights
2 months ago
Quick Summary
Alto Neuroscience (NYSE: ANRO) reported its full-year financial results for 2024, highlighting advancements in its pipeline of precision medicines for neuropsychiatric disorders.
Why It Matters
Alto Neuroscience's financial results and pipeline progress indicate potential growth in the neuropsychiatric market, impacting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation
2 months ago
Quick Summary
The Schall Law Firm is investigating Alto Neuroscience (NYSE:ANRO) for potential securities law violations, focusing on possible misleading statements to investors.
Why It Matters
Alto Neuroscience faces potential legal issues for misleading investors, which could impact stock value and investor confidence, prompting scrutiny of the company's financial health and governance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
The Schall Law Firm is investigating Alto Neuroscience, Inc. (NYSE:ANRO) for potential securities law violations, including false statements and undisclosed information affecting investors.
Why It Matters
Alto Neuroscience faces potential legal issues over misleading statements, which could impact stock performance and investor confidence, signaling heightened risk in its shares.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About ANRO Stock
What is Alto Neuroscience Inc.'s (ANRO) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Alto Neuroscience Inc. (ANRO) has a median price target of $10.00. The highest price target is $18.00 and the lowest is $4.00.
Is ANRO stock a good investment in 2025?
According to current analyst ratings, ANRO has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.93. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANRO stock?
Wall Street analysts predict ANRO stock could reach $10.00 in the next 12 months. This represents a 241.3% increase from the current price of $2.93. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alto Neuroscience Inc.'s business model?
The company utilizes advanced neurobiological insights and digital tools to create tailored treatments for mental health conditions such as depression and anxiety. By employing AI-driven patient profiling and biomarker-based approaches, Alto Neuroscience generates revenue through the development and commercialization of personalized therapeutic solutions, improving treatment efficacy and patient outcomes.
What is the highest forecasted price for ANRO Alto Neuroscience Inc.?
The highest price target for ANRO is $18.00 from Justin Walsh at Jones Trading, which represents a 514.3% increase from the current price of $2.93.
What is the lowest forecasted price for ANRO Alto Neuroscience Inc.?
The lowest price target for ANRO is $4.00 from Laura Chico at Wedbush, which represents a 36.5% increase from the current price of $2.93.
What is the overall ANRO consensus from analysts for Alto Neuroscience Inc.?
The overall analyst consensus for ANRO is bullish. Out of 7 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are ANRO stock price projections?
Stock price projections, including those for Alto Neuroscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 2:07 AM UTC